Patel R N
Enzyme Technology, Process Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute, One Squibb Drive, P.O. Box 191, New Brunswick, NJ 08903, USA.
Biomol Eng. 2001 Jun;17(6):167-82. doi: 10.1016/s1389-0344(01)00068-5.
Biocatalytic processes were used to prepare chiral intermediates required for the synthesis of Omapatrilat 1 by three different routes. The synthesis and enzymatic conversion of 2-keto-6-hydroxyhexanoic acid 3 to L-6-hydroxynorleucine 2 was demonstrated by reductive amination using beef liver glutamate dehydrogenase. To avoid the lengthy chemical synthesis of the ketoacid 3, a second route was developed to prepare the ketoacid by treatment of racemic 6-hydroxy norleucine [readily available from hydrolysis of 5-(4-hydroxybutyl) hydantoin 4] with D-amino acid oxidase from porcine kidney or Trigonopsis variabilis followed by reductive amination to convert the mixture completely to L-6-hydroxynorleucine in 98% yield and 99% enantiomeric excess (e.e.). The enzymatic synthesis of (S)-2-amino-5-(1,3-dioxolan-2-yl)-pentanoic acid (allysine ethylene acetal, 5) was demonstrated using phenylalanine dehydrogenase (PDH) from T. intermedius. Phenylalanine dehydrogenase was cloned and overexpressed in Escherichia coli and Pichia pastoris. Using PDH from E. coli or P. pastoris, the enzymatic process was scale-up to prepare kg quantity of allysine ethylene acetal 5. The reaction yields of >94% and e.e. of >98% were obtained for allysine ethylene acetal 5. An enzymatic process was developed for the synthesis of [4S-(4a,7a,10ab)]1-octahydro-5-oxo-4 [[(phenylmethoxy)carbonyl]amino]-7H-pyrido-[2,1-b] [1,3]thiazepine-7-carboxylic acid [BMS-199541-01]. The enzymatic oxidation of the epsilon-amino group of lysine in the dipeptide dimer N(2)-[N[[(phenyl-methoxy)carbonyl] L-homocysteinyl] L-lysine)-1,1-disulphide [BMS-201391-01] to produce BMS-199541-01 using a novel L-lysine epsilon-aminotransferase (LAT) from Sphingomonas paucimobilis SC 16113 was demonstrated. This enzyme was overexpressed in E. coli and a process was developed using the recombinant enzyme.
生物催化过程被用于通过三种不同路线制备合成奥美帕替诺(Omapatrilat 1)所需的手性中间体。使用牛肝谷氨酸脱氢酶通过还原胺化反应证明了2-酮-6-羟基己酸3合成L-6-羟基正亮氨酸2以及其酶促转化过程。为避免酮酸3冗长的化学合成,开发了第二条路线,即通过用来自猪肾或可变三角酵母的D-氨基酸氧化酶处理外消旋6-羟基正亮氨酸(可从5-(4-羟丁基)乙内酰脲4水解轻松获得)来制备酮酸,随后进行还原胺化反应,以98%的产率和99%的对映体过量(e.e.)将混合物完全转化为L-6-羟基正亮氨酸。使用中间嗜热栖热放线菌的苯丙氨酸脱氢酶(PDH)证明了(S)-2-氨基-5-(1,3-二氧戊环-2-基)-戊酸(烯赖氨酸乙烯缩醛,5)的酶促合成。苯丙氨酸脱氢酶在大肠杆菌和毕赤酵母中进行了克隆和过表达。使用来自大肠杆菌或毕赤酵母的PDH,该酶促过程放大到可制备千克量的烯赖氨酸乙烯缩醛5。烯赖氨酸乙烯缩醛5的反应产率>94%,对映体过量>98%。开发了一种酶促过程用于合成[4S-(4a,7a,10ab)]1-八氢-5-氧代-4-[[(苯基甲氧基)羰基]氨基]-7H-吡啶并-[2,1-b][1,3]硫氮杂卓-7-羧酸[BMS-199541-01]。使用来自少动鞘氨醇单胞菌SC 16113的新型L-赖氨酸ε-氨基转移酶(LAT),证明了二肽二聚体N(2)-[N[[(苯基甲氧基)羰基]L-高半胱氨酰]L-赖氨酸]-1,1-二硫化物[BMS-201391-01]中赖氨酸的ε-氨基的酶促氧化以产生BMS-199541-01。该酶在大肠杆菌中过表达,并使用重组酶开发了一个过程。